62778 Federal Register / Vol. 62, No. 227 / Tuesday, November 25, 1997 / Notices

FDA regrets that it was unable to

publish this notice 15 days prior to the

December 4, 1997, Circulatory System

Devices Panel of the Medical Devices

Advisory Committee meeting. Because

the agency believes there is some

urgency to bring this issue to public

discussion and qualified members of the

Circulatory System Devices Panel of the

Medical Devices Advisory Committee

were available at this time, the

Commissioner concluded that it was in

the public interest to hold this meeting

even if there was not sufficient time for

the customary 15-day public notice.

Closed Committee Deliberations: On

December 4, 1997, from 9 a.m. to 5 p.m.,

the meeting will be closed to permit

discussion and review of trade secret

and/or confidential commercial

information on a product development

protocol. This portion of the meeting

will be closed to permit discussion of

this information (5 U.S.C. 552b (c)(4)).

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: November 20, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–31064 Filed 11–21–97; 11:12

am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Notice of Meeting of the Advisory

Committee to the Director, NIH

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

Advisory Committee to the Director,

NIH, December 4, 1997, Conference

Room 10, Building 31, National

Institutes of Health, Bethesda, Maryland

20892.

The entire meeting will be open to the

public from 8:30 a.m. to adjournment.

The topics proposed for discussion

include: (1) Center for Scientific

Review; (2) Report from the Clinical

Research Panel; (3) New Investigator

Awards, Modular Awards, and Clinical

Research Training; (4) Report from the

Working Group on Research Tools; (5)

Implementation of the Government

Performance and Results Act; and (6)

Report on the Review of Administrative

Functions at NIH. Attendance by the

public will be limited to space available.

Ms. Janice Ramsden, Special Assistant

to the Deputy Director, National

Institutes of Health, 1 Center Drive MSC

0159, Bethesda, Maryland 20892–0159,

telephone (301) 496–0959, fax (301)

496–7451, will furnish the meeting

agenda, roster of committee members,

and available substantive program

information upon request. Any

individual who requires special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contact Ms.

Ramsden no later than November 26,

1997.

Dated: November 18, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–30931 Filed 11–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of Public

Law 92–463, as amended, notice is

hereby given of a meeting of the

President’s Cancer Panel, National

Cancer Institute. This meeting will be

closed to the public in accordance with

the provisions set forth in sec.

552b(c)(9)(B), Title 5, U.S.C. The

purpose of this meeting is to plan the

1997 Final Report of the Chairman to

the President and to set agendas for the

upcoming 1998 panel meetings.

Premature disclosure of the specific

details of these discussions and

recommendations would be likely to

significantly frustrate the subsequent

implementation of the proposed

recommendations made by the Panel.

Linda Quick-Cameron, Committee

Management Officer, National Cancer

Institute, Executive Plaza North, Room

609, 6130 Executive Blvd., MSC 7410,

Bethesda, MD 20892–7410 (301/496–

5708) will provide a copy of the roster

of committee members upon request.

Other information pertaining to the

meeting may be obtained from the

contact person indicated below.

Committee Name: President’s Cancer

Panel.

Date: December 1, 1997.

Place: Hyatt Regency Bethesda, 1

Bethesda Metro Center, Bethesda, MD

20814.

Closed: 10:30 a.m. to Adjournment.

Agenda: Discussion and preparation

of the 1997 Final Report of the

Chairman to the President and set

agendas for the 1998 meetings.

Contact Person: Maureen O. Wilson,

Ph.D., Executive Secretary, National

Cancer Institute, Building 31, Room

4A48, 9000 Rockville Pike, MSC 2473,

Bethesda, MD 20892–2473, Telephone:

(301) 496–1148.

Dated: November 6, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–30926 Filed 11–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting of the National Cancer

Advisory Board and Its Subcommittees

Pursuant to the Federal Advisory

Committee Act, as amended, notice is

hereby given of the meeting of the

National Cancer Advisory Board

(Board), National Cancer Institute (NCI),

and its Subcommittees on December 2–

3, 1997. The meetings of the Board and

its Subcommittees will be open to the

public as indicated below. Attendance

by the public will be limited to space

available.

A portion of the Board meeting will

be closed to the public in accordance

with the provisions set forth in sections

552b(c)(6) and 552b(c)(9)(B), Title 5

U.S.C. and section 10(d) of the Federal

Advisory Committee Act, as amended,

for discussions pertaining to NCI

personnel and programmatic issues.

These discussions could reveal

information of a personal nature where

disclosure would constitute a clearly

unwarranted invasion of personal

privacy and would be likely to

significantly frustrate the subsequent

implementation of personnel and

programmatic recommendations made

during these discussions.

The Committee Management Office,

National Cancer Institute, National

Institutes of Health, Executive Plaza

North, Room 609, 6130 Executive

Boulevard, MSC 7410, Bethesda,

Maryland 20892–7410, (301) 496–5708

will provide summaries of the meetings

and rosters of the Board members, upon

request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Mrs. Linda Quick-Cameron,

Committee Management Officer, at (301)

496–5708 in advance of the meeting.

Name of Committee: National Cancer

Advisory Board.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room